Edwards Lifesciences Corp. - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Edwards Lifesciences is a global leader in structural heart disease innovation. The company recently completed the sale of its Critical Care product group in September 2024, which is now reported as discontinued operations. The company continues to focus on implantable medical innovations for structural heart disease, organized into four geographic segments: United States, Europe, Japan, and Rest of World.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $1,412.7 | $1,329.9 |
| Gross Profit | $1,111.1 | $1,043.0 |
| Gross Margin | 78.6% | 78.4% |
| Operating Income | $394.8 | $349.0 |
| Net Income (Continuing Ops) | $363.6 | $324.9 |
| Net Income (Total) | $356.4 | $351.0 |
| Diluted EPS | $0.61 | $0.58 |
| Operating Cash Flow | $280.4 | $(53.5) |
| Cash & Equivalents | $3,140.6 | $3,045.2 |
| Long-term Debt | $597.8 | $597.7 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.2% year-over-year, driven by strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT) and Transcatheter Aortic Valve Replacement (TAVR).
- Discontinued Operations: The company reported a net loss of $7.2 million from discontinued operations in Q1 2025, compared to income of $26.1 million in Q1 2024, following the sale of the Critical Care business.
- Operating Expenses: SG&A expenses increased to $465.7 million (from $428.4 million) due to higher field-based personnel costs and professional services related to transition agreements. R&D expenses decreased slightly to $254.6 million.
- Cash Flow: Operating cash flow improved significantly to $280.4 million, primarily due to a large tax payment of $349.2 million made in Q1 2024 that did not recur in the same magnitude in Q1 2025.
- Share Repurchases: The company repurchased 3.4 million shares for $306.9 million, including a $250 million accelerated share repurchase (ASR) agreement.
Guidance, Outlook, and Risks
- Product Approvals: In April 2025, the company received FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients and CE Mark for the SAPIEN M3 mitral valve replacement system.
- Tax Outlook: The effective tax rate for continuing operations was 16.2% in Q1 2025, up from 12.5% in Q1 2024, driven by global minimum tax ("Pillar Two") impacts. The company expects Pillar Two to result in approximately $60 million in additional tax expense for 2025.
- Legal Contingencies: Significant uncertainties remain regarding an IRS Notice of Deficiency for tax years 2015-2017 (seeking ~$269.3 million in additional tax) and an assessment by the Israel Tax Authority (~$110 million). The company is vigorously contesting these matters.
- Acquisitions: The company has agreements to acquire multiple medical device companies with a total aggregate cash purchase price of $1.5 billion. One transaction is expected to close in 2025.
Investor Verification Checklist
- Tax Disputes: Verify the status and potential financial impact of the ongoing IRS transfer pricing litigation (2015-2017) and the Israel Tax Authority assessment.
- Discontinued Operations: Confirm the final working capital adjustments and transition service agreement (TSA) income related to the Critical Care sale.
- Share Repurchase Program: Monitor the settlement of the $250 million ASR agreement scheduled for July 2025 and the remaining $1.1 billion authorization.
- Regulatory Approvals: Track the commercial uptake of the newly approved SAPIEN 3 platform for asymptomatic patients and the SAPIEN M3 system.
- Acquisition Integration: Assess the integration progress and milestone payment triggers for the pending $500 million acquisition closing in 2025.